Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Design and interim safety analysis of GeparX trial

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.18
Views: 482
Rating:

Prof Sibylle Loibl - German Breast Cancer Group, Frankfurt, Germany

Dr Loibl speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about the trail arms and early indications from the Gepar X trial investigating denosumab as a neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-paclitaxel schedules.

Dr Loibl also spoke with ecancer about the Gepar Nuevo trial, here

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

War on Cancer 2018


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation